|
|
|
|
|
Biperiden
drug data and news
Biperiden drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Biperiden | ||
| Brand Names/Synonyms | Akineton; Akineton Hydrochloride; Akinophyl; Beperiden; Biperiden; Biperiden Hydrochloride; Biperiden [Usan:Ban:Inn:Jan]; Biperidene Hydrochloride; Biperidene [Inn-French]; Biperideno [Inn-Spanish]; Biperidenum [Inn-Latin]; Biperidine; Biperidine Hydrochloride; CHEMBANK2609; KL 373 | ||
| Indication | For use as an adjunct in the therapy of all forms of parkinsonism and control of extrapyramidal disorders secondary to neuroleptic drug therapy. | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Biperiden is a weak peripheral anticholinergic agent. It has, therefore, some antisecretory, antispasmodic and mydriatic effects. In addition, biperiden possesses nicotinolytic activity. The parenteral form of biperiden is an effective and reliable agent for the treatment of acute episodes of extrapyramidal disturbances sometimes seen during treatment with neuroleptic agents. Akathisia, akinesia, dyskinetic tremors, rigor, oculogyric crisis, spasmodic torticollis, and profuse sweating are markedly reduced or eliminated. With parenteral biperiden, these drug-induced disturbances are rapidly brought under control. | ||
| Mechanism Of Action | Parkinsonism is thought to result from an imbalance between the excitatory (cholinergic) and inhibitory (dopaminergic) systems in the corpus striatum. The mechanism of action of centrally active anticholinergic drugs such as biperiden is considered to relate to competitive antagonism of acetylcholine at cholinergic receptors in the corpus striatum, which then restores the balance. | ||
| Biperiden News (When available) |
| ||
| Dosage Forms | TABLET | ||
| Drug_Category | Antiparkinson Agents; Antidyskinetics; Muscarinic Antagonists; Parasympatholytics; ATC:N04AA02 | ||
| Absorption | 87% bioavailability | ||
| Interactions |
Interactions for Biperiden: Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines. See OVERDOSAGE section for signs and symptoms of the central anticholinergic syndrome, and for treatment. | ||
| Toxicity | Oral, rat LD50: 760 mg/kg. Signs of overdose include dilated and sluggish pupils; warm, dry skin; facial flushing; decreased secretions of the mouth, pharynx, nose, and bronchi; foul-smelling breath; elevated temperature, tachycardia, cardiac arrhythmias, decreased bowel sounds, urinary retention, delirium, disorientation, anxiety, hallucinations, illusions, confusion, incoherence, agitation, hyperactivity, ataxia, loss of memory, paranoia, combativeness, and seizures. | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | 1-(5-bicyclo[2.2.1]hept-2-enyl)-1-phenyl-3-(1-piperidyl)propan-1-ol | ||
| Chemical Formula | C21H29NO | ||
| Molecular Weight | 311.461 g/mol | ||
| Smiles String | C1CCN(CC1)CCC(C2CC3CC2C=C3)(C4=CC=CC=C4)O | ||
| Melting Point | 114 °C | ||
| Water Solubility | 25.1 mg/L | ||
| State | Solid | ||
| LogP/Hphobicity | 3.85 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | The metabolism of biperiden is not completely understood, but does involve hydroxylation. | ||
| Half Life | Not Available | ||
| Protein Binding [%] | 60% | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Biperiden.html http://www.rxlist.com/cgi/generic2/biperiden.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00725 | ||
| CAS Registry Number | 514-65-8 | ||
| KEGG Compound ID | C07941 | ||
| PubChem ID | SID:153864 | ||
| PharmGKB ID | PA448626 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 124982 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |